Search Results1-6 of  6

  • SUNAKAWA Yu ID: 9000006834520

    Department of Medical Oncology, Comprehensive Cancer Center, Saitama Medical University (2008 from CiNii)

    Articles in CiNii:2

    • CYP2A6 and the plasma level of 5-chloro-2,4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1 (2008)
    • Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI) (2008)
  • SUNAKAWA Yu ID: 9000257891914

    Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University (2012 from CiNii)

    Articles in CiNii:1

    • Association of <i>ABCC2</i> Genotype with Efficacy of First-line FOLFIRI in Japanese Patients with Advanced Colorectal Cancer (2012)
  • Sunakawa Yu ID: 9000242546550

    Articles in CiNii:1

    • Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for sn-38, an active metabolite of irinotecan, in humans (2014)
  • Sunakawa Yu ID: 9000258575699

    Department of Medical Oncology, Saitama International Medical Center-Comprehensive Cancer Center, Saitama Medical University (2009 from CiNii)

    Articles in CiNii:1

    • Pharmacokinetics of S-1 in elderly Japanese patients with cancer (2009)
  • Sunakawa Yu ID: 9000258576793

    International Medical Center-Comprehensive Cancer Center, Saitama Medical University (2010 from CiNii)

    Articles in CiNii:1

    • THE SMALL-MOLECULE TYROSINE KINASE INHIBITOR NILOTINIB IS A POTENT NONCOMPETITIVE INHIBITOR OF THE SN-38 GLUCURONIDATION BY HUMAN UGT1A1 (2010)
  • Sunakawa Yu ID: 9000258577364

    Department of Medical Oncology, International Medical Center-Comprehensive Cancer Center, Saitama Medical University (2010 from CiNii)

    Articles in CiNii:1

    • SEVERE RENAL FAILURE REQUIRING DIALYSIS CAUSES DELAYED ELIMINATION OF SN-38 IN CANCER PATIENTS WHO RECEIVE IRINOTECAN (2010)
Page Top